Abstract
Neurofibromatosis (NF) types 1 and 2 are classified as phacomatoses with an autosomal-dominant inheritance pattern. They are important in the field of neuro-oncology as they predispose affected patients to a number of CNS tumors including acoustic schwannoma, meningioma, glioma, ependymoma, and malignant peripheral nerve sheath tumor (MPNST). Management of tumors in patients with NF can differ from that in the non-NF population owing to a natural history that may be more aggressive, a greater need to preserve function in patients with acoustic schwannoma, and the concern for increased risk of radiation-induced tumors in this population. The management of NF-related acoustic schwannoma, meningioma, and MPNST is discussed here, while management of glioma and ependymoma is presented in separate chapters.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet. 2009;373(9679):1974–86.
Wishart JH. Case of tumours in the skull, dura mater and brain. Edinburgh Med Surg J. 1822;18:393–7.
Rouleau GA, Wertelecki W, Haines JL, et al. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature. 1987;329(6136):246–8.
Seizinger BR, Rouleau GA, Ozelius LJ, et al. Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell. 1987;49(5):589–94.
Evans DG, Moran A, King A, et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol. 2005;26(1):93–7.
Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. 1992;29(12):841–6.
Evans DG, Trueman L, Wallace A, et al. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet. 1998;35(6):450–5.
Parry DM, MacCollin MM, Kaiser-Kupfer MI, et al. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996;59(3):529–39.
Evans DG, Baser ME, O'Reilly B, et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg. 2005;19(1):5–12.
Brackmann DE, Fayad JN, Slattery WH 3rd, et al. Early proactive management of vestibular schwannomas in neurofibromatosis type 2. Neurosurgery. 2001;49(2):274–80. discussion 80–3
Khrais T, Romano G, Sanna M. Nerve origin of vestibular schwannoma: a prospective study. J Laryngol Otol. 2008;122(2):128–31.
Slattery WH 3rd, Brackmann DE, Hitselberger W. Hearing preservation in neurofibromatosis type 2. Am J Otol. 1998;19(5):638–43.
Jaaskelainen J, Paetau A, Pyykko I, et al. Interface between the facial nerve and large acoustic neurinomas. Immunohistochemical study of the cleavage plane in NF2 and non-NF2 cases. J Neurosurg. 1994;80(3):541–7.
Baser ME, Makariou EV, Parry DM. Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2. J Neurosurg. 2002;96(2):217–22.
Slattery WH 3rd, Fisher LM, Iqbal Z, et al. Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol. 2004;25(5):811–7.
Dirks MS, Butman JA, Kim HJ, et al. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. J Neurosurg. 2012;117(1):109–17.
Fisher LM, Doherty JK, Lev MH, et al. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium. Otol Neurotol. 2009;30(6):835–41.
Masuda A, Fisher LM, Oppenheimer ML, et al. Hearing changes after diagnosis in neurofibromatosis type 2. Otol Neurotol. 2004;25(2):150–4.
Plotkin SR, Merker VL, Muzikansky A, et al. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol. 2014;35(1):e50–6.
Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012;33(6):1046–52.
Ruggieri M, Pratico AD, Evans DG. Diagnosis, management, and new therapeutic options in childhood neurofibromatosis type 2 and related forms. Semin Pediatr Neurol. 2015;22(4):240–58.
Kida Y, Kobayashi T, Tanaka T, et al. Radiosurgery for bilateral neurinomas associated with neurofibromatosis type 2. Surg Neurol. 2000;53(4):383–9. discussion 9–90
Linskey ME, Lunsford LD, Flickinger JC. Tumor control after stereotactic radiosurgery in neurofibromatosis patients with bilateral acoustic tumors. Neurosurgery. 1992;31(5):829–38. discussion 38–9
Mallory GW, Pollock BE, Foote RL, et al. Neurosurgery. 2014;74(3):292–300. discussion −1
Mathieu D, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery. 2007;60(3):460–8. discussion 8–70
Roche PH, Regis J, Pellet W, et al. Neurofibromatosis type 2. Preliminary results of gamma knife radiosurgery of vestibular schwannomas. Neurochirurgie. 2000;46(4):339–53. discussion 54
Rowe JG, Radatz MW, Walton L, et al. Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry. 2003;74(9):1288–93.
Subach BR, Kondziolka D, Lunsford LD, et al. Stereotactic radiosurgery in the management of acoustic neuromas associated with neurofibromatosis Type 2. J Neurosurg. 1999;90(5):815–22.
Bush DA, McAllister CJ, Loredo LN, et al. Fractionated proton beam radiotherapy for acoustic neuroma. Neurosurgery. 2002;50(2):270–3. discussion 3–5
Harsh GR, Thornton AF, Chapman PH, et al. Proton beam stereotactic radiosurgery of vestibular schwannomas. Int J Radiat Oncol Biol Phys. 2002;54(1):35–44.
Vernimmen FJ, Mohamed Z, Slabbert JP, et al. Long-term results of stereotactic proton beam radiotherapy for acoustic neuromas. Radiother Oncol. 2009;90(2):208–12.
Weber DC, Chan AW, Bussiere MR, et al. Proton beam radiosurgery for vestibular schwannoma: tumor control and cranial nerve toxicity. Neurosurgery. 2003;53(3):577–86. discussion 86–8
Lunsford LD, Niranjan A, Flickinger JC, et al. Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J Neurosurg. 2005;102(Suppl):195–9.
Bari ME, Forster DM, Kemeny AA, et al. Malignancy in a vestibular schwannoma. Report of a case with central neurofibromatosis, treated by both stereotactic radiosurgery and surgical excision, with a review of the literature. Br J Neurosurg. 2002;16(3):284–9.
Baser ME, Evans DG, Jackler RK, et al. Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer. 2000;82(4):998.
Noren G. Long-term complications following gamma knife radiosurgery of vestibular schwannomas. Stereotact Funct Neurosurg. 1998;70(Suppl 1):65–73.
Thomsen J, Mirz F, Wetke R, et al. Intracranial sarcoma in a patient with neurofibromatosis type 2 treated with gamma knife radiosurgery for vestibular schwannoma. Am J Otol. 2000;21(3):364–70.
Comey CH, McLaughlin MR, Jho HD, et al. Death from a malignant cerebellopontine angle triton tumor despite stereotactic radiosurgery. Case report. J Neurosurg. 1998;89(4):653–8.
Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84(304):603–18.
Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996;38(5):880–5. discussion 5–6
Patronas NJ, Courcoutsakis N, Bromley CM, et al. Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology. 2001;218(2):434–42.
Perry A, Giannini C, Raghavan R, et al. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol. 2001;60(10):994–1003.
Slattery WH. Neurofibromatosis type 2. Otolaryngol Clin N Am. 2015;48(3):443–60.
Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child. 1999;81(6):496–9.
Ardern-Holmes S, Fisher G, North K. Neurofibromatosis type 2: presentation, major complications, and management, with a focus on the pediatric age group. J Child Neurol. 2017;32(1):9–22
Bosch MM, Wichmann WW, Boltshauser E, et al. Optic nerve sheath meningiomas in patients with neurofibromatosis type 2. Arch Ophthalmol. 2006;124(3):379–85.
Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. J Neurooncol. 2010;99(3):341–7.
Baser ME, Friedman JM, Aeschliman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet. 2002;71(4):715–23.
Evans DG, Sainio M, Baser ME. Neurofibromatosis type 2. J Med Genet. 2000;37(12):897–904.
Roser F, Nakamura M, Martini-Thomas R, et al. The role of surgery in meningiomas involving the optic nerve sheath. Clin Neurol Neurosurg. 2006;108(5):470–6.
Santacroce A, Walier M, Regis J, et al. Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients. Neurosurgery. 2012;70(1):32–9. discussion 9
Kondziolka D, Madhok R, Lunsford LD, et al. Stereotactic radiosurgery for convexity meningiomas. J Neurosurg. 2009;111(3):458–63.
Wentworth S, Pinn M, Bourland JD, et al. Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int J Radiat Oncol Biol Phys. 2009;73(1):208–13.
Birckhead B, Sio TT, Pollock BE, et al. Gamma Knife radiosurgery for neurofibromatosis type 2-associated meningiomas: a 22-year patient series. J Neuro-Oncol. 2016;130(3):553–60.
Liu A, Kuhn EN, Lucas JT Jr, et al. Gamma Knife radiosurgery for meningiomas in patients with neurofibromatosis Type 2. J Neurosurg. 2015;122(3):536–42.
Huang JH, Zhang J, Zager EL. Diagnosis and treatment options for nerve sheath tumors. Expert Rev Neurother. 2005;5(4):515–23.
Louis DN, Ohgaki H, Wiestler OD, et al. WHO classification of tumours of the central nervous system. Lyon, France: International Agency for Research on Cancer; 2016.
Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39(5):311–4.
LaFemina J, Qin LX, Moraco NH, et al. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann Surg Oncol. 2013;20(1):66–72.
Seferis C, Torrens M, Paraskevopoulou C, et al. Malignant transformation in vestibular schwannoma: report of a single case, literature search, and debate. J Neurosurg. 2014;121(Suppl):160–6.
Byerly S, Chopra S, Nassif NA, et al. The role of margins in extremity soft tissue sarcoma. J Surg Oncol. 2016;113(3):333–8.
Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305–15.
Ferrari A, Bisogno G, Carli M. Management of childhood malignant peripheral nerve sheath tumor. Paeditr Drugs. 2007;9:239–48.
Derlin T, Tornquist K, Munster S, et al. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med. 2013;38(1):e19–25.
Valentin T, Le Cesne A, Ray-Coquard I, et al. Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer. 2016;56:77–84.
Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009;249(6):1014–22.
Kolberg M, Holand M, Agesen TH, et al. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neurooncology. 2013;15(2):135–47.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Struve, T.D., Pater, L.E., Breneman, J. (2018). NF2-Related Tumors and Malignant Peripheral Nerve Sheath Tumors. In: Chang, E., Brown, P., Lo, S., Sahgal, A., Suh, J. (eds) Adult CNS Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42878-9_23
Download citation
DOI: https://doi.org/10.1007/978-3-319-42878-9_23
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42877-2
Online ISBN: 978-3-319-42878-9
eBook Packages: MedicineMedicine (R0)